Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Operating Leases (2019 - 2026)

Sunshine Biopharma filings provide 5 years of Operating Leases readings, the most recent being $596785.0 for Q4 2025.

  • On a quarterly basis, Operating Leases fell 19.86% to $596785.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $596785.0, a 19.86% decrease, with the full-year FY2025 number at $596785.0, down 19.86% from a year prior.
  • Operating Leases hit $596785.0 in Q4 2025 for Sunshine Biopharma, down from $636708.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $744724.0 in Q4 2024 to a low of $440298.0 in Q3 2024.
  • Median Operating Leases over the past 4 years was $596850.0 (2023), compared with a mean of $596466.0.
  • Biggest five-year swings in Operating Leases: dropped 22.44% in 2024 and later soared 52.63% in 2025.
  • Sunshine Biopharma's Operating Leases stood at $642232.0 in 2022, then fell by 16.07% to $539035.0 in 2023, then soared by 38.16% to $744724.0 in 2024, then decreased by 19.86% to $596785.0 in 2025.
  • The last three reported values for Operating Leases were $596785.0 (Q4 2025), $636708.0 (Q3 2025), and $706530.0 (Q2 2025) per Business Quant data.